Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Pre-Tax Margin

Income before tax as a percentage of revenue.

Niagen Bioscience IncNASDAQ: NAGE

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 21.4%

Pre-tax margin was 21.4% in Q1 FY2026, up 4.2 pp from a year earlier. On a trailing-twelve-month basis it was 15.1%, up 1.6 pp year over year. Over 3 fiscal years it widened by 37.0 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.4%+8.3 pp QoQ
Last fiscal yearDec 2025
14.1%+5.2 pp YoY
LTMMar 2026
15.1%+1.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.2 pp——
1 year+5.2 pp——
3 years+37.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.1%
Year-over-year change
+5.2pp

Pre-Tax Margin vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 pre-tax margin of 15.1% is the 3rd highest of the 8 companies compared; the peer median is -121.8%.
  • Its year-over-year change of +1.6 pp is the 4th highest of 7, against a peer median of -41.3 pp.
  • Over three fiscal years its change of +37.0 pp compares with a peer median of +90.1 pp.
NAGE Competitors Peer median
Pre-Tax Margin for NAGE and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026109.1% +294.8 pp+345.2 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202640.7% +21.9 pp+90.1 pp
NAGENiagen Bioscience IncLTM Mar 202615.1% +1.6 pp+37.0 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-8.1% +16.4 pp+30.6 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-121.8% ——
PRTAProthena Corporation plcLTM Mar 2026-182.9% -98.9 pp-1840.8 pp
KROSKeros Therapeutics, Inc.LTM Mar 2026-272.2% -278.9 pp—
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+135.0 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NAGE) -121.8%-41.3 pp+90.1 pp

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue67.45M72.05M83.57M99.6M129.42M
Cost of Revenue25.96M29.25M32.79M38.01M46.23M
Gross Profit41.49M42.8M50.78M61.59M83.19M
Gross Margin61.5%59.4%60.8%61.8%64.3%
Research & Development3.83M4.83M4.96M6.02M6.33M
Selling, General & Admin64.73M56.6M51.42M47.84M62.56M
Operating Expenses68.56M61.43M56.38M53.86M68.89M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
EBITDA(25.45M)(14.66M)(3.23M)10.34M19.64M
EBITDA Margin-37.7%-20.3%-3.9%10.4%15.2%
Operating Income(27.07M)(18.63M)(5.6M)7.73M14.3M
Operating Margin-40.1%-25.9%-6.7%7.8%11.0%
Interest Income03K661K1.13M2.13M
Interest Expense55K0000
Other Income / Expenses(55K)2.09M661K1.13M3.9M
Income Before Tax(27.13M)(16.54M)(4.94M)8.86M18.19M
Pre-Tax Margin-40.2%-23.0%-5.9%8.9%14.1%
Income Tax Expense000305K810K
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Net Margin-40.2%-23.0%-5.9%8.6%13.4%
EPS (Basic)(0.40)(0.24)(0.07)0.100.22
EPS (Diluted)(0.40)(0.24)(0.07)0.110.20
Weighted Avg Shares67.19M68.92M70.54M85.42M79.18M
Weighted Avg Shares (Diluted)67.19M69.73M74.99M79.72M85.44M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.